Literature DB >> 9650960

The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.

A Touze1, S El Mehdaoui, P Y Sizaret, C Mougin, N Muñoz, P Coursaget.   

Abstract

The L1 major capsid proteins of six human papillomavirus type 16 (HPV-16) strains were expressed in insect cells by using recombinant baculoviruses. Virus-like particles (VLPs) which appeared similar to empty virions were identified by electron microscopy for all HPV strains investigated. However, the yield of VLPs produced varied in a range from 1 to 79 depending on the HPV-16 strain. The L1 proteins of these strains differed by up to 15 amino acids from the L1 protein of the prototype HPV-16 strain. Mutations in the amino acid region from residues 83 to 97 seemed to affect the level of expression of the L1 protein. These results are important when considering the development of HPV vaccines and serological tests. They indicate that strains inducing high levels of VLP production must be selected for the development of vaccines. Moreover, the L1 proteins of all strains investigated were able to bind with DNA. We also investigated the seroreactivities of VLPs derived from three different HPV-16 strains from Algeria, Senegal, and the Philippines by testing sera from women from 11 countries in immunoglobulin G-specific enzyme-linked immunosorbent assays. We observed a strong correlation between the reactivities of the three different VLP variants, independent of the geographical origin of the sera investigated. These results indicate that the three strains investigated are serologically cross-reactive despite the fact that their L1 proteins differ in 14 amino acids and suggest that VLPs derived from only one HPV-16 strain could be sufficient for the development of an HPV-16 vaccine and anti-HPV-16 tests.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9650960      PMCID: PMC104976     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Characterization of the DNA-binding properties of the polyomavirus capsid protein VP1.

Authors:  R B Moreland; L Montross; R L Garcea
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

Review 2.  Human papillomaviruses: general features.

Authors:  M Favre; N Ramoz; G Orth
Journal:  Clin Dermatol       Date:  1997 Mar-Apr       Impact factor: 3.541

3.  Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction.

Authors:  T S Baker; W W Newcomb; N H Olson; L M Cowsert; C Olson; J C Brown
Journal:  Biophys J       Date:  1991-12       Impact factor: 4.033

Review 4.  Cancer and infection: estimates of the attributable fraction in 1990.

Authors:  P Pisani; D M Parkin; N Muñoz; J Ferlay
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-06       Impact factor: 4.254

5.  Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11.

Authors:  N D Christensen; J W Kreider; N M Cladel; S D Patrick; P A Welsh
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

6.  Antibody-mediated neutralization in vivo of infectious papillomaviruses.

Authors:  N D Christensen; J W Kreider
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

Review 7.  Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers.

Authors:  H zur Hausen
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

8.  Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

Authors:  J Zhou; X Y Sun; D J Stenzel; I H Frazer
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

9.  Human papillomavirus type 16 DNA sequence.

Authors:  K Seedorf; G Krämmer; M Dürst; S Suhai; W G Röwekamp
Journal:  Virology       Date:  1985-08       Impact factor: 3.616

10.  Molecular variants of human papillomavirus type 16 from four continents suggest ancient pandemic spread of the virus and its coevolution with humankind.

Authors:  S Y Chan; L Ho; C K Ong; V Chow; B Drescher; M Dürst; J ter Meulen; L Villa; J Luande; H N Mgaya
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more
  26 in total

Review 1.  The viral etiology of AIDS-associated malignancies.

Authors:  Peter C Angeletti; Luwen Zhang; Charles Wood
Journal:  Adv Pharmacol       Date:  2008

2.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

3.  Saccharomyces cerevisiae is permissive for replication of bovine papillomavirus type 1.

Authors:  Kong-Nan Zhao; Ian H Frazer
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy.

Authors:  Maxime J J Fleury; Antoine Touzé; Pierre Coursaget
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

5.  Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions.

Authors:  Latifa Bousarghin; Alba-Lucia Combita-Rojas; Antoine Touzé; Slimane El Mehdaoui; Pierre-Yves Sizaret; Maria-Mercedes Bravo; Pierre Coursaget
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

6.  Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes.

Authors:  A Touzé; S de Sanjosé; P Coursaget; M R Almirall; V Palacio; C J Meijer; J Kornegay; F X Bosch
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

7.  Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.

Authors:  Maxime J J Fleury; Antoine Touzé; Silvia de Sanjosé; F Xavier Bosch; Joellen Klaustermeiyer; Pierre Coursaget
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

8.  Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.

Authors:  Nicolas Combelas; Emilie Saussereau; Maxime J J Fleury; Tatiana Ribeiro; Julien Gaitan; Diego F Duarte-Forero; Pierre Coursaget; Antoine Touzé
Journal:  J Transl Med       Date:  2010-03-24       Impact factor: 5.531

9.  Baculovirus expression of chimeric hepatitis B virus core particles with hepatitis E virus epitopes and their use in a hepatitis E immunoassay.

Authors:  A Touze; N Enogat; Y Buisson; P Coursaget
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

10.  Specificity of L1 peptides versus virus-like particles for detection of human papillomavirus-positive cervical lesions in females attending Engativa Hospital, Bogota, Colombia.

Authors:  Mauricio Urquiza; Ricardo Sánchez; Jairo Amaya; Sandra León; Jenny Acosta; Manuel A Patarroyo; Milena Camargo; Manuel E Patarroyo
Journal:  J Clin Microbiol       Date:  2008-09-17       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.